Compounds > fulvestrant
Page last updated: 2024-08-26

fulvestrant and Endometrial Neoplasms

fulvestrant has been researched along with Endometrial Neoplasms in 31 studies

Research

Studies (31)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's6 (19.35)18.2507
2000's15 (48.39)29.6817
2010's9 (29.03)24.3611
2020's1 (3.23)2.80

Authors

AuthorsStudies
Chen, G; Ge, Y; Jin, J; Jin, X; Li, J; Ye, M1
Jiang, A; Li, G; Ren, C; Wang, G; Yang, T; Yu, Z; Zhang, Q1
Breitbach, GP; Camara, O; Emons, G; Finas, D; Günthert, A; Kölbl, H; Reimer, T; Rensing, K; Strauss, HG; Thiel, FC1
Arts, HJ; Glaudemans, AW; Hollema, H; Hospers, GA; Reyners, AK; van Kruchten, M1
Dolcet, X; Domingo, M; Dosil, MA; Eritja, N; Llombart-Cussac, A; Matias-Guiu, X; Mirantes, C; Santacana, M; Valls, J1
Wang, JL; Zhang, LL1
Battista, MJ; Schmidt, M1
Bogliolo, S; Cassani, C; Dominoni, M; Ferrero, S; Gardella, B; Iacobone, AD; Orlandini, A; Spinillo, A; Venturini, PL; Viazzo, F1
Boehme, K; Mueller, SO; Simon, S1
Bonebrake, A; Covens, AL; Filiaci, V; Gersell, D; Lee, YC; Lutman, CV1
Feng, Y; Liao, H; Wei, Y; Wu, L; Wu, X; Xi, X; Zhang, Z; Zhou, D; Zhu, Y1
Chan, S1
Farnell, YZ; Ing, NH1
Hopert, AC; Schubert, C; Strunck, E; Tüshaus, L; Vollmer, G; Wünsche, W1
Bjeldanes, LF; Firestone, GL; Leong, H; Riby, JE1
Kudo, R; Saito, T; Tanaka, R; Wataba, K; Yamasaki, H1
McDonald, D; Morrissey, C; O'Sullivan, J; Schneider, MR; Tenniswood, MP; Vollmer, G; Wünsche, W; Zierau, O1
Blok, LJ; Burger, CW; Gielen, SC; Hanifi-Moghaddam, P; Kühne, LC1
Abram, P; Vergote, I1
Hoffman, MA; Khan, A1
Gao, M; Li, XP; Sun, PM; Wang, JL; Wei, LH; Zhao, D1
Guo, RX; Li, XP; Wang, JL; Wei, LH; Zhao, D1
Adachi, S; Arima, T; Asanoma, K; Kato, K; Kinoshita, K; Ohgami, T; Suga, S; Wake, N; Yamaguchi, S; Yamayoshi, A1
Amodio, R; Carruba, G; Castagnetta, LA; Granata, OM; Liquori, M; Montesanti, AM; Oliveri, G; Sorci, CM1
Belanger, A; Gauthier, S; Labrie, C; Labrie, F; Merand, Y; Poirier, D; Sanchez, R; Simard, J; Singh, SM1
Assikis, VJ; Bilimoria, MM; Chatterton, R; Cisneros, A; Dragan, YP; England, GM; Jordan, VC; MacGregor, JI; Muenzner, HD; O'Regan, RM; Piette, M; Pitot, HC1
DeGregorio, MW1
Williams, GM1
Ellmén, J; Kaukonen, M; Mäenpää, J; Pasanen, T1
Appa Rao, KB; Gui, Y; Lessey, BA; Lovely, LP1
Kunselman, AR; Legro, RS; Miller, SA; Satyaswaroop, PG1

Reviews

5 review(s) available for fulvestrant and Endometrial Neoplasms

ArticleYear
Positron emission tomography imaging of oestrogen receptor-expression in endometrial stromal sarcoma supports oestrogen receptor-targeted therapy: case report and review of the literature.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:18

    Topics: Adult; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Positron-Emission Tomography; Receptors, Estrogen; Sarcoma, Endometrial Stromal; Time Factors; Treatment Outcome; Tumor Burden

2013
Fulvestrant for the treatment of endometrial cancer.
    Expert opinion on investigational drugs, 2016, Volume: 25, Issue:4

    Topics: Animals; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans

2016
The role of fulvestrant in endometrial cancer.
    Expert opinion on drug metabolism & toxicology, 2017, Volume: 13, Issue:5

    Topics: Animals; Antineoplastic Agents, Hormonal; Biological Availability; Disease Progression; Endometrial Neoplasms; Estradiol; Estrogen Receptor Antagonists; Female; Fulvestrant; Humans; Quality of Life

2017
A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer.
    Seminars in oncology, 2002, Volume: 29, Issue:3 Suppl 11

    Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Piperidines; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Thiophenes

2002
Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:2

    Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Joint Diseases; Nitriles; Postmenopause; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles

2006

Trials

2 trial(s) available for fulvestrant and Endometrial Neoplasms

ArticleYear
Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynäkologische Onkologie.
    Gynecologic oncology, 2013, Volume: 129, Issue:3

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Drug Administration Schedule; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Injections, Intramuscular; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Receptors, Estrogen; Receptors, Progesterone

2013
Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study.
    Gynecologic oncology, 2011, Volume: 120, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Disease-Free Survival; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Receptors, Estrogen; Receptors, Progesterone

2011

Other Studies

24 other study(ies) available for fulvestrant and Endometrial Neoplasms

ArticleYear
Endometrial cancer (EC) derived G3BP1 overexpression and mutant promote EC tumorigenesis and metastasis via SPOP/ERα axis.
    Cell communication and signaling : CCS, 2023, 10-30, Volume: 21, Issue:1

    Topics: Cell Transformation, Neoplastic; DNA Helicases; Endometrial Neoplasms; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Male; Poly-ADP-Ribose Binding Proteins; RNA Helicases; RNA Recognition Motif Proteins; Ubiquitination

2023
RIZ1 is regulated by estrogen and suppresses tumor progression in endometrial cancer.
    Biochemical and biophysical research communications, 2017, 07-22, Volume: 489, Issue:2

    Topics: Animals; Cell Proliferation; Disease Progression; DNA-Binding Proteins; Down-Regulation; Drug Screening Assays, Antitumor; Endometrial Neoplasms; Estradiol; Estrogens; Female; Fulvestrant; Histone-Lysine N-Methyltransferase; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Nuclear Proteins; Structure-Activity Relationship; Transcription Factors; Tumor Cells, Cultured

2017
Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells.
    Molecular cancer therapeutics, 2014, Volume: 13, Issue:4

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Cycle; Cell Line, Tumor; Endometrial Neoplasms; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Mice; Mice, SCID; Mutation; Neoplasms, Experimental; Quinolones; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Xenograft Model Antitumor Assays

2014
[Nongenomic effects of estrogen on extracellular signal-regulated kinases through initiating transient calcium flux in endometrial cancer].
    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2015, Jun-18, Volume: 47, Issue:3

    Topics: Calcium; Calcium Channel Blockers; Calcium Signaling; Endometrial Neoplasms; Estradiol; Estrogen Receptor Antagonists; Estrogens; Extracellular Signal-Regulated MAP Kinases; Female; Fulvestrant; Humans; Nifedipine; Phosphorylation; Receptors, Estrogen; Serum Albumin, Bovine

2015
Gene expression profiling in Ishikawa cells: a fingerprint for estrogen active compounds.
    Toxicology and applied pharmacology, 2009, Apr-01, Volume: 236, Issue:1

    Topics: Benzhydryl Compounds; Cell Line, Tumor; Cluster Analysis; DDT; Diethylstilbestrol; Endocrine Disruptors; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genistein; Humans; Oligonucleotide Array Sequence Analysis; Phenols; Phytoestrogens; Polymerase Chain Reaction; Receptors, Estrogen; Reproducibility of Results; Resveratrol; Risk Assessment; RNA, Messenger; Stilbenes; Time Factors; Zearalenone

2009
Nuclear estrogen receptor-mediated Notch signaling and GPR30-mediated PI3K/AKT signaling in the regulation of endometrial cancer cell proliferation.
    Oncology reports, 2012, Volume: 27, Issue:2

    Topics: Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Receptor, Notch1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Signal Transduction

2012
The effects of estradiol and selective estrogen receptor modulators on gene expression and messenger RNA stability in immortalized sheep endometrial stromal cells and human endometrial adenocarcinoma cells.
    The Journal of steroid biochemistry and molecular biology, 2003, Volume: 84, Issue:4

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Hormonal; Blotting, Northern; Cells, Cultured; Cloning, Molecular; Down-Regulation; Endometrial Neoplasms; Endometrium; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Humans; Receptors, Progesterone; RNA, Messenger; Selective Estrogen Receptor Modulators; Sheep; Stromal Cells; Time Factors; Transforming Growth Factor alpha; Tumor Cells, Cultured; Up-Regulation

2003
Estrogenic and antiestrogenic regulation of MMP-2 and MMP-13 mRNA in RUCA-I endometrial tumor cells in vitro and in vivo.
    Cancer letters, 2003, Jul-30, Volume: 198, Issue:1

    Topics: Adenocarcinoma; Collagenases; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Estrogens; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Matrix Metalloproteinase 13; Matrix Metalloproteinase 2; RNA, Messenger; Tumor Cells, Cultured

2003
Potent ligand-independent estrogen receptor activation by 3,3'-diindolylmethane is mediated by cross talk between the protein kinase A and mitogen-activated protein kinase signaling pathways.
    Molecular endocrinology (Baltimore, Md.), 2004, Volume: 18, Issue:2

    Topics: Adenocarcinoma; Anticarcinogenic Agents; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dependent Protein Kinases; Cycloheximide; Endometrial Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Flavonoids; Fulvestrant; Humans; Indoles; Isoquinolines; Ligands; MAP Kinase Signaling System; Phosphoprotein Phosphatases; Phosphorylation; Point Mutation; Sulfonamides; Transcription Factors; Transcriptional Activation; Tumor Cells, Cultured

2004
Overexpression of estrogen receptor-alpha gene suppresses gap junctional intercellular communication in endometrial carcinoma cells.
    Oncogene, 2004, Feb-05, Volume: 23, Issue:5

    Topics: Cell Communication; Cell Division; Cell Line, Tumor; Connexin 26; Connexins; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fluorescent Dyes; Fulvestrant; Gap Junction beta-1 Protein; Gap Junctions; Gene Expression Regulation, Neoplastic; Humans; Isoquinolines; Receptors, Estrogen

2004
Tamoxifen exerts agonistic effects on clusterin and complement C3 gene expression in RUCA-I primary xenografts and metastases but not normal uterus.
    Endocrine-related cancer, 2004, Volume: 11, Issue:4

    Topics: Animals; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Complement C3; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Neoplasm Metastasis; Rats; Rats, Inbred Strains; RNA, Messenger; Tamoxifen; Transplantation, Heterologous; Uterus

2004
Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin.
    Journal of the Society for Gynecologic Investigation, 2005, Volume: 12, Issue:7

    Topics: Amphiregulin; Antineoplastic Agents, Hormonal; EGF Family of Proteins; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gene Expression Profiling; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen; Transcription, Genetic; Tumor Cells, Cultured

2005
Durable response of metastatic endometrial carcinoma to treatment with fulvestrant (Faslodex) after prior progestin and anastrozole therapy.
    Gynecologic oncology, 2006, Volume: 100, Issue:2

    Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Endometrial Neoplasms; Estradiol; Female; Fulvestrant; Humans; Lung Neoplasms; Nitriles; Progestins; Triazoles

2006
[Regulatory effect of 17beta-estradiol on expression of orphan nuclear receptor ERRalpha in endometrial carcinoma cell lines].
    Ai zheng = Aizheng = Chinese journal of cancer, 2006, Volume: 25, Issue:5

    Topics: Cell Line, Tumor; Dose-Response Relationship, Drug; Endometrial Neoplasms; ERRalpha Estrogen-Related Receptor; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; Receptors, Estrogen; RNA, Messenger; Signal Transduction

2006
[Effects of ICI182780 (Faslodex) on proliferation and apoptosis induced by 17beta-estradiol in endometrial carcinoma cells].
    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2006, Oct-18, Volume: 38, Issue:5

    Topics: Adenocarcinoma; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Flow Cytometry; Fulvestrant; Humans

2006
An inhibitory effect on cell proliferation by blockage of the MAPK/estrogen receptor/MDM2 signal pathway in gynecologic cancer.
    Gynecologic oncology, 2007, Volume: 105, Issue:2

    Topics: Cell Growth Processes; Cell Line, Tumor; Down-Regulation; Endometrial Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Ovarian Neoplasms; Proto-Oncogene Proteins c-mdm2; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; Tumor Suppressor Protein p53

2007
17 beta-Hydroxysteroid dehydrogenase activity in endometrial cancer cells: different metabolic pathways of estradiol in hormone-responsive and non-responsive intact cells.
    The Journal of steroid biochemistry and molecular biology, 1995, Volume: 55, Issue:5-6

    Topics: Cell Division; Endometrial Neoplasms; Estradiol; Estradiol Dehydrogenases; Female; Fulvestrant; Humans; Radioligand Assay; Receptors, Estrogen; Receptors, Progesterone; Tumor Cells, Cultured

1995
Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells.
    Cancer research, 1997, Aug-15, Volume: 57, Issue:16

    Topics: Adenocarcinoma; Alkaline Phosphatase; Benzopyrans; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Neoplasm Proteins; Piperidines; Propionates; Raloxifene Hydrochloride; Tamoxifen; Toremifene; Tumor Cells, Cultured

1997
Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.
    Journal of the National Cancer Institute, 1998, Oct-21, Volume: 90, Issue:20

    Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Disease Models, Animal; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Mice; Mice, Nude; Ovariectomy; Tamoxifen; Toremifene

1998
Re: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.
    Journal of the National Cancer Institute, 1999, Mar-03, Volume: 91, Issue:5

    Topics: Antineoplastic Agents, Hormonal; Cell Division; Endometrial Neoplasms; Endometrium; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Tamoxifen; Toremifene

1999
Re: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.
    Journal of the National Cancer Institute, 1999, Apr-21, Volume: 91, Issue:8

    Topics: Animals; Antineoplastic Agents, Hormonal; Cell Transformation, Neoplastic; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Mice; Neoplasms, Hormone-Dependent; Tamoxifen; Toremifene

1999
Re: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.
    Journal of the National Cancer Institute, 1999, Jun-02, Volume: 91, Issue:11

    Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Risk; Tamoxifen; Toremifene

1999
Characterization of androgen receptors in a well-differentiated endometrial adenocarcinoma cell line (Ishikawa).
    The Journal of steroid biochemistry and molecular biology, 2000, Nov-15, Volume: 74, Issue:4

    Topics: Adenocarcinoma; Alkaline Phosphatase; Androgens; Cell Differentiation; Cell Nucleus; Diethylstilbestrol; Dihydrotestosterone; Endometrial Neoplasms; Endometrium; Estradiol; Estrogen Receptor Modulators; Estrogens; Female; Flutamide; Fulvestrant; Humans; Metribolone; Progesterone; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured

2000
Role of androgens in the growth of endometrial carcinoma: an in vivo animal model.
    American journal of obstetrics and gynecology, 2001, Volume: 184, Issue:3

    Topics: Androgens; Animals; Aromatase; Blotting, Western; Carcinoma; Disease Models, Animal; Electrophoresis, Agar Gel; Endometrial Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Orchiectomy; Regression Analysis; Testosterone; Transplantation, Heterologous

2001